Open Access Open Access  Restricted Access Subscription Access

An Important Parameters of Carbamazipine Include Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Health Care Outcomes

Moni Theresa Tsappidi, Muralinath E., Srinivas G., Guruprasad M., Ramanjaneyulu D.V.

Abstract


Acute manic and mixed episodes in bipolar I disorder, trigeminal neuralgia, and epilepsy can all be effectively managed and treated with carbamazepine. Partial seizures, mixed seizure patterns, generalized tonic seizures (grand mal), and complicated symptomatology (psychomotor, temporal lobe) are the main indications for epilepsy. This activity provides information on carbamazepine's off-label usage, mechanism of action, dosage, side effects, contraindications, and other important details.


Full Text:

PDF

References


Dean, L. (2015). Carbamazepine therapy and HLA genotype. In V. M. Pratt, S. A. Scott, M. Pirmohamed, B. Esquivel, B. L. Kattman, & A. J. Malheiro (Eds.), Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US).

Ceron-Litvoc, D., Soares, B. G., Geddes, J., Litvoc, J., & de Lima, M. S. (2009). Comparison of carbamazepine and lithium in treatment of bipolar disorder: A systematic review of randomized controlled trials. Human Psychopharmacology: Clinical and Experimental, 24(1), 19–28.

Liu, L., Zheng, T., Morris, M. J., Wallengren, C., Clarke, A. L., Reid, C. A., Petrou, S., & O'Brien, T. J. (2006). The mechanism of carbamazepine aggravation of absence seizures. Journal of Pharmacology and Experimental Therapeutics, 319(2), 790–798.

Owen, R. T. (2006). Extended-release carbamazepine for acute bipolar mania: A review. Drugs Today, 42(5), 283–289.

Englisch, S., & Zink, M. (2012). Treatment-resistant schizophrenia: Evidence-based strategies. Mens Sana Monographs, 10(1), 20–32.

Winkelmann, J., Allen, R. P., Högl, B., Inoue, Y., Oertel, W., Salminen, A. V., Winkelman, J. W., Trenkwalder, C., & Sampaio, C. (2018). Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017). Movement Disorders, 33(7), 1077–1091.

Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. American Journal of Psychiatry, 155(1), 54–61.

Wiffen, P. J., Derry, S., Moore, R. A., & Kalso, E. A. (2014). Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews, 2014(4), CD005451.

Latifi, S., & Messer, T. (2019). The efficacy of tiapride and carbamazepine combination therapy in reducing alcohol withdrawal symptoms: A systematic review and meta-analysis. Pharmacopsychiatry, 52(5), 209–216.

Peselow, E. D., Clevenger, S., & IsHak, W. W. (2016). Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: A naturalistic study. International Clinical Psychopharmacology, 31(4), 218–223.

Gambeta, E., Chichorro, J. G., & Zamponi, G. W. (2020). Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments. Molecular Pain, 16, 1744806920901890.

Gierbolini, J., Giarratano, M., & Benbadis, S. R. (2016). Carbamazepine-related antiepileptic drugs for the treatment of epilepsy – A comparative review. Expert Opinion on Pharmacotherapy, 17(7), 885–888.

Tonekaboni, S. H., Jafari, N., Mansouri, M., Jabbehdari, S., Eftekhari, R., Chavoshzadeh, Z., Abdollah Gorji, F., & Mesdaghi, M. (2017). HLA-B*1502 in Iranian children with anticonvulsant drugs-induced skin reactions. Iranian Journal of Child Neurology, 11(2), 26–30.

Ferrell, P. B., & McLeod, H. L. (2008). Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics, 9(10), 1543–1546.

Gandelman, M. S. (1994). Review of carbamazepine-induced hyponatremia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 18(2), 211–233.

Hmouda, H., Ben Salem, C., Grira, M., Slim, R., & Bouraoui, K. (2007). Carbamazepine-induced urinary retention. British Journal of Clinical Pharmacology, 64(6), 833–834.

Bertilsson, L. (1978). Clinical pharmacokinetics of carbamazepine. Clinical Pharmacokinetics, 3(2), 128–143.

Vajda, F. J. E., O'Brien, T. J., Graham, J., Lander, C. M., & Eadie, M. J. (2016). Is carbamazepine a human teratogen? Journal of Clinical Neuroscience, 23, 34–37.

Ornoy, A., Weinstein-Fudim, L., & Ergaz, Z. (2017). Antidepressants, antipsychotics, and mood stabilizers in pregnancy: What do we know and how should we treat pregnant women with depression? Birth Defects Research, 109(12), 933–956.

Verrotti, A., Scaparrotta, A., Grosso, S., Chiarelli, F., & Coppola, G. (2014). Anticonvulsant drugs and hematological disease. Neurological Sciences, 35(7), 983–993.


Refbacks

  • There are currently no refbacks.